Passer au contenu principal

Vincent Pichette

Pichette, Vincent

Full professor

Affiliation

Université de Montréal

Research Axes

Nephrology

Contact information

Phone: 514-252-3400, poste3340

vpichette.hmr@ssss.gouv.qc.ca

Team

  • Nathalie Henley
  • Daniel Feng

Dr. Vincent Pichette heads the Nephropharmacology Research Unit. A nephrologist at Hôpital Maisonneuve-Rosemont, Dr. Pichette is also very active in clinical research and is a full professor in the Faculty of Medicine and Faculty of Pharmacology at Université de Montréal.

Dr. Vincent Pichette is an experienced nephrologist and clinical pharmacologist with a long-standing interest in the impact of kidney failure on drug disposition and response. He is an authority on the use of experimental models in kidney disease and the use of these models to evaluate the effect of kidney disease and uremia on the functional expression of cytochrome P450 enzymes and drug transporters. The Pichette laboratory has published lead articles in this field demonstrating that uremia leads to the differential expression of CYPs and transporters in the liver and intestines.

Research Unit

Nephropharmacology

Research interests

  • Pharmacokinetics
  • Drug metabolism
  • Mechanisms of the regulation of cytochrome P450
  • Influence of kidney failure on pharmacokinetics
  • Mechanisms of transporter regulation
  • Pelletier K, Bonnefoy A, Chapdelaine H, Pichette V, Lejars M, Madore F, Brachemi S, Troyanov S. Clinical Value of Complement Activation Biomarkers in Overt Diabetic Nephropathy. Kidney Int Rep. 2019 Mar 20;4(6):797-805. doi: 10.1016/j.ekir.2019.03.004
    More detail
  • Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D; SONAR Committees and Investigators. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet. 2019 May 11;393(10184):1937-1947. doi: 10.1016/S0140-6736(19)30772-X
    More detail
  • Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744
    More detail
  • Jardine MJ, Mahaffey KW, Neal B, Agarwal R, Bakris GL, Brenner BM, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Pollock C, Wheeler DC, Xie J, Zhang H, Zinman B, Desai M, Perkovic V; CREDENCE study investigators. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. Am J Nephrol. 2017 Dec 13;46(6):462-472. doi: 10.1159/000484633
    More detail
  • Pineault J, Lamarche C, Bell R, Lafrance JP, Ouellet G, Leblanc M, Pichette V, Bezzaoucha S, Vallée M. Association of Neutrophil-to-Lymphocyte Ratio With Inflammation and Erythropoietin Resistance in Chronic Dialysis Patients. Can J Kidney Health Dis. 2017 Nov 3;4:2054358117735563. doi: 10.1177/2054358117735563
    More detail
  • Lepeytre F, Cardinal H, Fradette L, Verhave J, Dorais M, LeLorier J, Pichette V, Madore F. The impact of renal protection clinics on prescription of and adherence to cardioprotective drug therapy in chronic kidney disease patients. Clin Kidney J. 2017 Jun;10(3):375-380. doi: 10.1093/ckj/sfw144
    More detail
  • Dion F, Dumayne C, Henley N, Beauchemin S, Arias EB, Leblond FA, Lesage S, Lefrançois S, Cartee GD, Pichette V. Mechanism of insulin resistance in a rat model of kidney disease and the risk of developing type 2 diabetes. PLoS One. 2017 May 1;12(5):e0176650. doi: 10.1371/journal.pone.0176650
    More detail
  • Mawad H, Bouchard H, Tran D, Ouimet D, Lafrance JP, Bell RZ, Bezzaoucha S, Boucher A, Collette S, Pichette V, Senécal L, Vallée M. Retrospective Study Looking at Cinacalcet in the Management of Hyperparathyroidism after Kidney Transplantation. J Transplant. 2017;2017:8720283. doi: 10.1155/2017/8720283
    More detail
  • Rauscher S, Lafrance JP, Pichette V, Bell RZ, Desforges K, Lepage L, Ouellet G, Ouimet D, Leblanc M, Lamarche C, Bezzaoucha S, Vallee M. Conversion of oral alfacalcidol to oral calcitriol in the treatment of secondary hyperparathyroidism in chronic hemodialysis patients. Int Urol Nephrol. 2017 Feb;49(2):325-328. doi: 10.1007/s11255-016-1446-1
    More detail
  • Mawad H, Laurin LP, Naud JF, Leblond FA, Henley N, Vallée M, Pichette V, Leblanc M. Changes in Urinary and Serum Levels of Novel Biomarkers after Administration of Gadolinium-based Contrast Agents. Biomark Insights. 2016 Jun 29;11:91-4. doi: 10.4137/BMI.S39199
    More detail
  • Fradette C, Pichette V, Sicard É, Stilman A, Jayashankar S, Tsang YC, Spino M, Tricta F. Effects of renal impairment on the pharmacokinetics of orally administered deferiprone. Br J Clin Pharmacol. 2016 Oct;82(4):994-1001. doi: 10.1111/bcp.13037
    More detail

Education

  • Doctor of Medicine

    Université de Montréal

  • Internal medicine specialty certification (Quebec)

  • Royal College of Physicians and Surgeons of Canada (Internal Medicine)

    FRCPC

  • Certificate in nephrology

    CSPQ and FRCPC

  • PhD in pharmacology

    Université de Montréal

Awards

  • 2006 Senior Clinical Research Scholar  (FRQS)